Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01840150 · ClinicalTrials.gov registry record · NA
Study to Evaluate NA-NOSE for Monitoring and Detecting Recurrence in Early Stage Lung Cancer
A NA study, sponsored by Fox Chase Cancer Center.
- Completed
- Registry status
- NA
- Development phase
- 41
- Enrollment target
NCT01840150 is a NA study that has completed, run by Fox Chase Cancer Center. The registered enrollment target is 41 participants.
The verdict
NCT01840150, a NA study, has completed, sponsored by Fox Chase Cancer Center.
- COMPLETED
- Registry status
- NA
- Development phase
- 41 participants
- Enrollment target
Study Summary
This clinical trial studies nanoscale artificial nose (NA-NOSE) in monitoring response and detecting recurrence after surgery or radiation therapy in patients with stage I or stage II non-small cell lung cancer (NSCLC). Using the NA-NOSE breath test may be an effective way to monitor response and detect recurrence of NSCLC after surgery or radiation therapy.
Interventions
- OTHER laboratory biomarker analysis
- PROCEDURE breath test
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 41 participants |
| Start Date | 2012-08-23 |
| Est. Completion | 2019-07-05 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01840150
The ClinicalTrials.gov registry entry for NCT01840150 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 41 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Fox Chase Cancer Center, which has 183 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which laboratory biomarker analysis is the first listed.
NCT01840150 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01840150 about?
NCT01840150 is a clinical study titled "Study to Evaluate NA-NOSE for Monitoring and Detecting Recurrence in Early Stage Lung Cancer". This clinical trial studies nanoscale artificial nose (NA-NOSE) in monitoring response and detecting recurrence after surgery or radiation therapy in patients with stage I or stage II non-small cell lung cancer (NSCLC). Using the NA-NOSE breath test may be an effective way to monitor response and de...
What is the current status of trial NCT01840150?
This trial is currently completed. It is a NA study. The enrollment target is 41 participants. The study started on 2012-08-23. Estimated completion is 2019-07-05.
What interventions are being tested in trial NCT01840150?
The interventions under investigation include: laboratory biomarker analysis (OTHER), breath test (PROCEDURE).
Who is sponsoring clinical trial NCT01840150?
This trial is sponsored by Fox Chase Cancer Center, which has 183 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.